Trials / Recruiting
RecruitingNCT06280924
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Multiple Myeloma Exercise Prehabilitation for Individuals Awaiting a Stem Cell Transplantation (MOTIVATE): A Randomized Controlled Feasibility Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant. We also hope to learn if this type of program, along with a flexible delivery format (in-person and virtual), helps in maintaining or improving physical fitness, muscle mass and strength, and quality of life during chemotherapy.
Detailed description
MOTIVATE is a multi-methods feasibility randomized trial. We will recruit a minimum of 30 individuals with multiple myeloma who are undergoing chemotherapy prior to a Stem Cell Transplant. The study will be conducted in two phases: Phase I: Feasibility Study The aim of this phase is to determine the feasibility and preliminary effectiveness of a 10-week exercise intervention compared to physical activity counseling alone. Phase II: Qualitative Study The aim of this phase is to evaluate the acceptability of the Healthy Eating Active Living (HEAL-ME) app design, program delivery/design, and perceived effectiveness of the intervention at the level of the participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Supported Exercise | Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant. |
| BEHAVIORAL | Standard Care | Participants will receive standard care |
Timeline
- Start date
- 2024-08-06
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2024-02-28
- Last updated
- 2026-02-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06280924. Inclusion in this directory is not an endorsement.